NEW YORK, NY--(Marketwire - Feb 10, 2012) - The annual Society of Critical Care Medicine Conference, attended by over 1,000 participants, was held in Houston, Texas from February 2 - 8, 2012. There were three research studies presented which involved the use of the Daxor (NYSE Amex: [ DXR ]) BVA-100. One study involving small (10 kilo) pigs was from the College of Veterinary Medicine, University of Florida in Gainesville, Florida. The study, which was partially funded by the National Institutes of Health (NIH) involved the utilization of the Daxor BVA-100 Blood Volume Analyzer to measure capillary leak in response to a bacterial toxin (LPS). Bacterial septicemia is a life-threatening situation in which the integrity of the capillaries are damaged and can no longer separate water and critical proteins such as albumin in the blood. When this occurs with great severity, the blood pressure may collapse, resulting in permanent organ damage as well as death. Albumin I¹³¹, utilized by the Blood Volume Analyzer, is a recognized blood marker to measure this phenomenon. The BVA-100 is the first automated instrument to measure the rate of this leak in a precise manner. This is the first study that clearly demonstrated that change in the transudation rate can occur very early and be detectable utilizing the Blood Volume Analyzer. It has been previously shown that this can occur in post-surgical patients and burn patients. The authors of the paper were Drs. Carsten Brandt, Andre Shih, Naveen Thuramalla, Garett Buckly, and Hunter Schrank.

The study utilized regular sample sizes as well as ultra small sample sizes because the company is considering developing an injectate model utilizing ultra-small samples for use in pediatric patients. The company has received a number of inquiries about utilization of the Blood Volume Analyzer to measure blood loss in pediatric patients, which is very difficult to quantify at the present time.

Another study entitled "Comparison of Blood Volume Measurement in Neonatal Animal Model" was conducted in conjunction with the Transonic Systems Corporation which manufactures an indirect probe to measure active circulating blood volume. This is not the same as total blood volume but has some value when conducted in conjunction with a total blood volume measurement. This study was also partially funded by the NIH. The company may conduct additional research studies in conjunction with the Transonic Corporation to expand possible uses of the Transonic probe when used in conjunction with the Blood Volume Analyzer.

The third study, "Comparison of Blood Volume Analysis Measured by Ultrasound Dilution Method and Radioisotope Dilution Technique" by Dr. Mihae Yu at The Queen's Medical Center. This study was similar to the neonatal animal model except that it was done on humans. The end result showed a loose correlation between the two systems, with a 20% variation. The staff at Queen's provided numerous recommendations to Transonic that would improve their system to make their report similar to the output of Daxor's BVA-100. They also noted the significant variability in results depending upon how fast the dilution was presented into the patient, thus recommending an automated pump to provide a consistent delivery of the tracer. Daxor believes that a hospital utilizing the BVA-100 to establish a baseline blood volume and then utilizing Transonic's flow system to look at changes might have some application. Significant changes and improvements to the Transonic product would be needed to achieve this.

Abstracts of the studies were published as a supplement in the December 2011 issue of the Journal of Critical Care Medicine.

Daxor Corporation manufactures and markets the BVA-100, which is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at [ www.Daxor.com ].